Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SPIRONOLACTONE

All products: general benefit

Other products in the same Health Canada class (C03D) — coverage varies; not interchangeable

  • Amiloride (Midamor): general benefit

Aldactone · DIN 00285455 · 100mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-17 — choose a marketed DIN from the same-category list.Discontinued 2026-07-17 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Aldactone · DIN 00285455 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2026-07-17 · brand ALDACTONE 100 MG · ATC C03DA01 SPIRONOLACTONE · form Tablet · route Oral · ingredients SPIRONOLACTONE 100 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0955 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2145 · Verify on the e-Formulary ↗ (DIN 00285455)

Source record
DIN 00285455: Aldactone Raw flags: chronicUseMed=Y, sec3=Y Item: 402800021; group id 567; item number 1513; lccId None; manufacturer id PFI Source form: Tab; strength: 100mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.6410; ministry $0.0955 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00285455 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2145
Interchangeable products
Jamp Spironolactone · DIN 02518848 · $0.0955 Mint-Spironolactone · DIN 02488159 · $0.0955 Teva-Spironolactone · DIN 00613223 · $0.0955
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2026-07-17 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, FUROSEMIDE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE, INDAPAMIDE 40:28 Diuretics

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

FUROSEMIDE

· 14 products · Limited Use, codes 481, 657 (2), General benefit (9), Listed, not a benefit (2), Limited Use, codes 33 (1) · strengths: 10mg/mL, 20mg, 40mg, 500mg · Inj Sol (Preservative Free), O/L, Tab

HYDROCHLOROTHIAZIDE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & TRIAMTERENE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg & 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab

TOLVAPTAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications TEVA-SPIRONOLACTONE (spironolactone) is indicated for: • Primary Hyperaldosteronism TEVA-SPIRONOLACTONE (spironolactone) is a useful agent in the diagnosis of primary hyperaldosteronism. In the presence of hypokalemic alkalosis and hypertension, a diagnosis of primary hyperaldosteronism should be considered if both blood pressure (BP) and serum electrolytes return to normal following treatment with TEVA-SPIRONOLACTONE. TEVA-SPIRONOLACTONE is useful in the pre-operative treatment of patients with primary hyperaldosteronism and for the maintenance therapy of such patients who decline surgery, or who are unsuitable for surgery. • Edematous Conditions o Congestive Heart Failure (CHF): TEVA-SPIRONOLACTONE is useful in the management of edema and sodium retention in CHF when the patient is only partially responsive to, or intolerant of, other therapeutic measures. TEVA-SPIRONOLACTONE may be used alone or with thiazides. It is indicated in patients with CHF taking digitalis when other therapies are considered inappropriate. o Cirrhosis of the Liver Accompanied by Edema and/or Ascites: … https://pdf.hres.ca/dpd_pm/00083325.PDF PM date: 2026-01-29 Source product: TEVA-SPIRONOLACTONE; DIN 00613215; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.